Description
This training is designed to provide foundational knowledge and skills in initiating buprenorphine treatment for opioid use disorder in the outpatient setting in the context of the widespread presence of illicitly manufactured fentanyl. We explore how the potency and prevalence of fentanyl complicates the initiation phase of buprenorphine treatment, leading to potential clinical challenges such as precipitated withdrawal. We suggest participating in the next training in the series, Buprenorphine 201, upon completing Buprenorphine 101.
Objectives
At the end of this training, participants will have the knowledge necessary to:
- Identify the impact of illicitly manufactured fentanyl on buprenorphine initiation and its unique challenges in treatment.
- Describe at least 2 strategies for initiating buprenorphine in individuals with opioid use disorder.
- Develop an individualized, comprehensive care plan for initiating buprenorphine in an outpatient setting.
Sponsored by
Boston Medical Center Grayken Center for Addiction TTA, Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS)
Funding for out of state attendees is provided by the Opioid Response Network (ORN).
Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Accreditation information
Please read the Accreditation Information section of the
training page to learn about the requirements for receiving credit or a certificate of completion.
Audience
Medical providers (physicians, advanced practice providers), nurses, and other clinical team members that support medical management of opioid use disorder.
